CDK4/6 inhibition enhances T-cell immunotherapy on hepatocellular carcinoma cells by rejuvenating immunogenicity

Xiurong Cai,Guo Yin,Shuai Chen,Frank Tacke,Adrien Guillot,Hanyang Liu
DOI: https://doi.org/10.1186/s12935-024-03351-z
IF: 6.429
2024-06-22
Cancer Cell International
Abstract:Hepatocellular carcinoma (HCC) poses a significant clinical challenge, necessitating the integration of immunotherapeutic approaches. Palbociclib, a selective CDK4/6 inhibitor, has demonstrated promising efficacy in preclinical HCC models and is being evaluated as a novel therapeutic option in clinical trials. Additionally, CDK4/6 inhibition induces cellular senescence, potentially influencing the tumor microenvironment and immunogenicity of cancer cells. In this study, we conducted comprehensive bioinformatic analyses using diverse HCC transcriptome datasets, including bulk and single-cell RNA-sequencing data from public databases. We also utilized human and mouse HCC cells to investigate functional aspects. Primary T cells isolated from mouse blood were employed to assess T cell immunity against HCC cells. Results revealed that CD8 + T-cell infiltration correlates with improved outcomes in HCC patients with suppressed CDK4/6 expression. Moreover, CDK4/6 expression was associated with alterations in the immune landscape and immune checkpoint expression within the liver tumor microenvironment. Furthermore, we found that treatment with Palbociclib and Doxorubicin induces cellular senescence and a senescence-associated secretory phenotype in HCC cells. Notably, pretreatment with Palbociclib augmented T cell-mediated cytotoxicity against HCC cells, despite upregulation of PD-L1, surpassing the effects of Doxorubicin pretreatment. In conclusion, our study elucidates a novel mechanism by which CDK4/6 inhibition enhances T-cell-associated cancer elimination and proposes a potential therapeutic strategy to enhance T-cell immunotherapy on HCC.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: how to enhance the immunotherapy effect of hepatocellular carcinoma (HCC) by inhibiting CDK4/6. Specifically, the study aims to explore the mechanism of action of the CDK4/6 inhibitor Palbociclib in HCC, especially how it improves the treatment effect on HCC by changing the tumor microenvironment and enhancing T - cell - mediated immune responses. ### Main problems: 1. **The relationship between CDK4/6 expression and HCC immune infiltration and prognosis**: - The study found that the expression of CDK4/6 is closely related to the immune cell infiltration and clinical prognosis of HCC patients. HCC patients with low CDK4/6 expression show better survival rates and lower disease recurrence rates. - The infiltration of CD8+ T cells is associated with low CDK6 expression, indicating a better disease outcome. 2. **The effects of Palbociclib and Doxorubicin on HCC cells**: - Both Palbociclib and Doxorubicin can significantly inhibit the proliferation of HCC cells and induce cell senescence. - HCC cells treated with Palbociclib show a higher level of inflammatory factor secretion, while Doxorubicin mainly causes cell damage and cell - cell interactions. - Palbociclib treatment also leads to an up - regulation of PD - L1 expression, but this up - regulation can be reversed by immune checkpoint blockade. 3. **The effect of CDK4/6 inhibition on the immunogenicity of HCC**: - CDK4/6 inhibition can change the inflammatory secretion of HCC cells and enhance their immunogenicity. - Single - cell transcriptome analysis shows that HCC cells with low CDK6 expression can transmit more biological signals to T cells, thereby activating the immune response of T cells. 4. **The effect of CDK4/6 - inhibition - dependent cell senescence on T - cell activity**: - Palbociclib - induced cell senescence can activate T cells and prevent T cells from losing function due to PD - 1/PD - L1 - mediated exhaustion. - The experimental results show that the PD - 1 blocker significantly enhances the killing ability of T cells against Palbociclib - induced senescent HCC cells, while the effect of the PD - L1 blocker is relatively limited. ### Conclusion: This study reveals a new mechanism by which the CDK4/6 inhibitor Palbociclib enhances the immunotherapy effect of HCC by changing the immunogenicity of HCC cells and activating T - cell - mediated immune responses. This provides a theoretical basis for the development of new HCC treatment strategies.